Why is the comparison with Medicare for SUFLAVE POWDER labelled estimated?

Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Suflave / PEG 3350/Sod Sulf,Chlr/Pot/Mag: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on brand name.

Why does this page start at 1 unit (EA)?

NADAC prices this product per EA, and the FDA NDC Directory lists 2 of its 3 NDCs (it does not list the other one) as dosage form “KIT” with no route. Only a tablet, capsule, lozenge or troche with route “ORAL”, or a tablet or film with route “SUBLINGUAL” or “BUCCAL”, starts at 30, and none of these is one. NADAC’s EA for it may be the whole kit or one item in it, and the files do not say which. So the card starts at 1 unit (EA) rather than guess how many make up a fill; change it to match your prescription.

SUFLAVE POWDER

FDA nonproprietary name: polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride for oral solution

For 1 unit (EA)

Pharmacies pay

$61.65 filed

1 × $61.64625 per EA

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-06-17, 2026-08-05 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D paid

$61.40 filed

1 × $61.40295 per EA, Part D average

Medicare's price is not your price.

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

The spread

1.0× estimated

Medicare paid about what pharmacies pay.

Part D averages every strength and form sold under “Suflave” / “PEG 3350/Sod Sulf,Chlr/Pot/Mag” into one figure, so it is not specific to this NDC.

OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-06-17, 2026-08-05 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)

Cost-plus estimate

$75.90 estimated

$61.65 + $9.25 (15%) + $5.00 fee per fill = $75.90

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-06-17, 2026-08-05 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

SUFLAVE POWDER is how the CMS NADAC file names this product. The FDA NDC Directory lists it as polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride for oral solution, under the trade name “SUFLAVE”.

FDA gives its dosage form as kit.

Its labelers, the companies named on the label, are Azurity Pharmaceuticals, Inc. and Braintree Laboratories, Inc.

FDA lists no Established Pharmacologic Class for it.

The NADAC file of 2026-10-14 prices it under 3 NDCs (National Drug Codes); the FDA directory lists 2 of them.

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $61.65 for 1 unit (EA) (1 × $61.64625 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; those prices took effect between 2026-06-17 and 2026-08-05. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 2, the latest survey was within 2% of the current NADAC, so the NADAC was carried forward from the previous file.

The NADAC of all 3 NDCs was carried forward from an earlier file (NADAC explanation code 2 or 4), not newly surveyed: those prices took effect on 2026-06-17, 2026-08-05. The file is new; the price is not.

What NADAC measures · NADAC explanation codes · Carried-forward prices

All 3 NDCs

24338-0550-01 · Azurity Pharmaceuticals, Inc. · $61.64625 per EA · eff. 2026-08-05 filed carried forward
52268-0550-01 · Braintree Laboratories, Inc. · $61.64625 per EA · eff. 2026-06-17 filed carried forward
52268-0551-01 · not listed as a package in the FDA directory · $61.64625 per EA · eff. 2026-06-17 filed carried forward

What Medicare paid

Medicare Part D paid $61.40 for 1 unit (EA), at an average of $61.40295 per EA in 2024 (2024-01-01 to 2024-12-31) for “Suflave” and “PEG 3350/Sod Sulf,Chlr/Pot/Mag”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 30,370 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

What is your cash price for 1 unit (EA)? Is it lower than what I would pay through my insurance?
If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.

Questions

Why is the comparison with Medicare for SUFLAVE POWDER labelled estimated?: Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Suflave / PEG 3350/Sod Sulf,Chlr/Pot/Mag: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on brand name.
Why does this page start at 1 unit (EA)?: NADAC prices this product per EA, and the FDA NDC Directory lists 2 of its 3 NDCs (it does not list the other one) as dosage form “KIT” with no route. Only a tablet, capsule, lozenge or troche with route “ORAL”, or a tablet or film with route “SUBLINGUAL” or “BUCCAL”, starts at 30, and none of these is one. NADAC’s EA for it may be the whole kit or one item in it, and the files do not say which. So the card starts at 1 unit (EA) rather than guess how many make up a fill; change it to match your prescription.